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Abstract 19 
There is growing awareness of the role of diet in both health and disease management.  Much 20 
data is available on the cardioprotective diet in the primary and secondary prevention of 21 
cardiovascular disease (CVD). However, there is limited information on the role of diet in the 22 
management of heart failure (HF). Animal models of HF have provided interesting insight 23 
and potential mechanisms by which dietary manipulation may improve cardiac performance 24 
and delay the progression of the disease, and small-scale human studies have highlighted 25 
beneficial diet patterns. The aim of this review is to summarise the current data available on 26 
the role of diet in the management of human HF and to demonstrate that dietary manipulation 27 
needs to progress further than the simple recommendation of salt and fluid restriction.  28 
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Introduction 46 
Heart failure (HF) represents a clinically defined end point that can be the result of 47 
many different cardiac diseases which impair ventricular function. Impaired ventricular 48 
function results in clinical signs of disease such as dyspnoea, fatigue and oedema. HF can be 49 
classified based upon the time course of events, the side of the heart affected, whether 50 
systolic or diastolic function is impaired, ejection fraction (EF), and the severity of 51 
symptoms(1). Mortality still remains high with HF, although data from the UK National Heart 52 
Failure audit shows in-hospital mortality has fallen from 11.1% to 9.5% between 2011/12 to 53 
2013/14(2,3). However, 6.2% of patients who survive to discharge die in the 30-days following 54 
discharge, and overall one-year mortality stands at 27%(3).  55 
In the UK, the most common New York Heart Association (NYHA) classification at 56 
time of first hospital admission is class III or IV, representing a total of 80% of those 57 
diagnosed with HF(3). Ischaemic heart disease (IHD) and hypertension (HTN) are observed in 58 
46% and 54% of HF patients, respectively(3) suggesting that both conditions are important 59 
risk factors for the development of HF. Indeed, a medical history of IHD is more likely to 60 
result in the diagnosis of left ventricular systolic dysfunction (LVSD) and hence reduced 61 
ejection fraction (EF) whereas HTN or valvular disease is associated with non-systolic HF 62 
with a preserved or normal EF (HFpEF)(3). This latter form of HF is more frequently 63 
observed in obese women with pre-existing diabetes(4) whereas male sex, smoking and prior 64 
MI are associated more strongly with HF with reduced EF (HFrEF)(5). Recognised 65 
comorbidities present in the HF population include anaemia, cachexia, cancer, chronic 66 
obstructive pulmonary disease (COPD), depression, diabetes, gout, hyperlipidaemia, HTN, 67 
iron-deficiency anaemia and renal dysfunction, all of which may require careful management 68 
in addition the condition of HF(1). Interestingly those patients with HFpEF tend to have a 69 
higher non-cardiac comorbidity burden when compared to patients with HFrEF(6), potentially 70 
identifying them as a unique patient group.  71 
In addition to the known medical causes, HF has important socioeconomically 72 
determinants. Individuals with HF living in the most deprived areas of the UK are more likely 73 
to present at a younger age when compared to those living is less deprived areas(3), suggesting 74 
additional factors – rather than just medical comorbidities – may influence prognosis. Such 75 
factors may include access to care, educational level but also lifestyle choices, including 76 
dietary habits. 77 
The evolving knowledge of substrate usage in the failing heart has prompted several 78 
investigators to re-examine the importance of dietary modification in this patient group. This 79 
manipulation has extended further than preventing uncontrolled weight loss, itself shown to 80 
be linked with greater incidence of mortality(7), to diet patterns linked with improvements in 81 
cardiac function and delayed mortality. It may be suggested that the window for nutritional 82 
intervention becomes narrower as HF progresses, with prevention of unintentional weight 83 
loss potentially more important in end-stage disease. Indeed, management of malnutrition and 84 
cachexia in HF patients is a key priority and has been reviewed extensively(8). 85 
There is a substantial gap in clinical guidance for the dietetic management of patients 86 
with HF, despite widely recognised nutritional deficiencies(9). Sodium restriction has been the 87 
significant nutritional recommendation by the American College of Cardiology 88 
Foundation/American Heart Association (ACCF/AHA) for the reduction of congestive 89 
symptoms(10) however this is not mirrored by European guidance(1), itself providing limited 90 
advice other than of fluid restriction, maintenance of healthy weight and prevention of 91 
malnutrition. Irrespective of sodium, both guidelines provide little information into additional 92 
dietary changes that may be of benefit to the patient. The aim of this review is to present 93 
current developments in the understanding of nutrition in HF and to highlight the areas that 94 
need crucial development.  95 
 96 
Ventricular remodelling 97 
Left ventricular hypertrophy (LVH) is an important step in the development of HF. 98 
LVH may initially be beneficial in normalising wall stress and haemodynamic function(11) 99 
and several animal models have suggested that inhibiting the initial hypertrophic process is 100 
detrimental(12,13). Pathological ventricular remodelling patterns have recently been shown to 101 
be associated with the incidence of HF and interestingly display differential risk for HF with 102 
HFpEF and HFrEF(13). Specifically, individuals with eccentric remodelling have a greater 103 
than 2-fold risk of developing HFrEF, whereas those with concentric changes showed 104 
increased risk of HFpEF. These statistics are of significance given the high prevalence of 105 
HTN and IHD in HF patients(3). 106 
 107 
  108 
Metabolic remodelling 109 
Ventricular remodelling processes also extend to metabolism and have been 110 
extensively reviewed(14-16). Classically the predominance of fatty acid (FA) oxidation (FAO) 111 
in the healthy heart is replaced by glycolytic substrate usage and reduced ability to utilise 112 
FAs in the failing heart(16,17) although this concept has been challenged(18). Indeed, the 113 
conflicting changes observed in anmial models may represent confounding factors such as the 114 
method used to induce HF, the strain of animal and duration of the intervention giving rise to 115 
different cardiac responses when challenged with varying diets(19). Nonetheless, in patients 116 
with NYHA Class IV HF the mRNA and protein levels for key enzymes associated with 117 
FAO are reduced, supporting the metabolic change(20). In addition to altered FAO there is 118 
evidence that mitochondrial oxidation of glucose may be diminished in HF(17) leading to a 119 
scenario where the heart cannot process sufficient FAs or glucose to maintain adequate 120 
energy supply. As such there is reduced ability to synthesise ATP leading to impaired 121 
contractile function. This concept of the failing heart being energy-starved is not new and is 122 
why the failing heart has been likened to “an engine out of fuel” (21). Many groups have used 123 
this concept to suggest that manipulation of the diet to facilitate sufficient ATP production 124 
may be important in regulating function in the failing heart.  125 
 126 
The role of lipid in heart failure 127 
Much of the work on dietary manipulation has been performed in experimental 128 
models of LVH and/or HF, and has been reviewed extensively(22,23). A limitation of such 129 
models is that whilst providing useful mechanistic insight, they do little to represent benefits 130 
in quality of life and reduced rates of hospital admission. However from these mechanistic 131 
studies there is evidence to suggest manipulation of nutrient intake – predominantly 132 
carbohydrate and fat content – has an important role in regulating cardiac structure and 133 
function in HF(24). The importance of fat is often overshadowed by its high energy content per 134 
gram, however in HF patients this same parameter may be beneficial in increasing an 135 
individual’s calorie intake and preventing unintentional weight loss and cachexia(8). Several 136 
animal studies have also shown a potential beneficial role of dietary fat that extends beyond 137 
calories, forcing us to question if we should be encouraging a greater intake of this 138 
macronutrient in the HF population. For example, coronary artery ligation in Wistar rats has 139 
shown to reduce stroke volume and EF, although this finding can be partially attenuated by 140 
the provision of a diet containing 60% lipid (25% palmitic acid, 33% stearic acid, and 33% 141 
oleic acid)(25). This study also demonstrated that the high-fat diet had no impact upon cardiac 142 
performance in response to a dobutamine stress test, suggesting no additional impairment to 143 
contractile reserve. Equally when failing hearts from rats fed a high-fat diet are perfused ex 144 
vivo they demonstrate an improvement in cardiac FAO which is similar to that of non-145 
infarcted controls(26). The authors of this study raise an important argument in that following 146 
a MI, providing sufficient fuel for the non-infarcted myocardium is vitally important as the 147 
burden of function is often shifted to healthy tissue. This is further compounded by the 148 
observation that acutely limiting the availability circulating FAs in patients with 149 
cardiomyopathic HF depresses cardiac function suggesting an important role of FAs in HF(27) 150 
(table 1).  151 
 152 
Cardiac triacylglycerol and lipotoxicity 153 
The ability to store and utilise endogenous triacylglycerol (TAG) has been shown to 154 
be important for cardiac function(28) and the role of endogenous TAG is particularly 155 
important in the context of cardiac lipotoxicity. The traditional view of lipotoxicity relies 156 
upon the concept that a reduced capacity of the cardiomyocyte to oxidise FAs coupled with 157 
normal or increased FA delivery leads to progressive lipid accumulation, the shuttling of FA 158 
species into the formation of biologically active intermediates such as diacylglycerol and 159 
ceramide, and ultimately cellular and organ dysfunction (29). An excellent review on the role 160 
of FAs and their derivatives as signalling molecules can be found in van Bilsen and 161 
Planavila(30). 162 
Traditional view of lipotoxicity being a pathology solely attributable to lipid 163 
accumulation is not completely accurate, and endogenous TAG accumulation may actually 164 
protect against biologically active intermediate formation with a specific role of various FAs 165 
in this process. Indeed previous research suggested that excessive supply of palmitate leads to 166 
increased apoptosis, and that provision of oleate in addition to palmitate can attenuate this by 167 
channelling palmitate into the formation of endogenous TAG and away from ceramide 168 
synthesis(31). Whislt impressive, this study was performed in a cell culture model and may not 169 
reflect the chronic nature of lipid accumulation in disease or the consequences of prolonged 170 
accumulation (table 1). Nonetheless, it reflects the complexity of lipid dynamics(32) and rasies 171 
questions over whether lipid accumulation per se is damaging, or wherther impairment to the 172 
dynamic nature of this enrgy store is more important. 173 
In HF endogenous TAG may be an important yet inaccessible source of substrate. The 174 
induction of HF in rats leads to a significant reduction in TAG turnover suggesting impaired 175 
access to this energy store(33). An inability to utilise stored TAG through decreased oxidation 176 
may lead to reduced energy provision in the setting of HF. Consequently improving the 177 
heart’s access to its own endogenous energy supply may have a significant impact upon 178 
cardiac function. In support of this theory, provision of oleate to failing hearts of Sprague 179 
Dawley rats maintains the myocardial TAG pool and increases TAG turnover when 180 
compared to palmitate(34). This finding was associated with improved cardiac contractility, 181 
augmentation of target genes associated with FAO and a reduction in the reactive 182 
intermediate C16 ceramide(34). Although performed in rodents, the significance of this study 183 
is that that via manipulating the exposure of the failing heart to different FA species, 184 
mechanical performance can be improved (table 1).  185 
 186 
Omega 3 intake in heart failure 187 
Omega-3 (n-3) supplementation is currently listed as a class IIb recommendation and 188 
level B evidence in patients with systolic HF in European guidance(1), with similar 189 
recommendations present in ACCF/AHA guidance(10).  190 
The Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Heart 191 
Failure (GISSI-HF) study demonstrated the advantageous method of supplementing stage II-192 
IV HF patients with 1g daily of an eicosapentaenoic acid (EPA)/docosahexaenoic acid 193 
(DHA) mix, however only producing a small yet significant reduction in hazard ratio for 194 
mortality compared to the placebo group(35) (table 2). A recent meta-analysis(36) has also 195 
confirmed the beneficial effect of n-3s on cardiac health and function in HF patients. In this 196 
study, pooled results of 4 studies totaling 350 participants showed fish oil supplementation to 197 
significantly reduce left ventricular LV end-systolic volume (LVESV) compared with 198 
placebo. Similarly analysis also suggested fish oil to be associated with improved LVEF(36). 199 
Whilst this meta-analysis supports the notion that fish oil supplementation may have a 200 
beneficial effect in patients with HF, it remains to be determined if similar effects can be 201 
observed by dietary sources alone.  202 
To draw further attention to the requirement of more research into diets specific to HF 203 
patients, the results of two recent systematic reviews and meta-analyses have provided. The 204 
first meta-analysis by Rizos et al.(37) considered randomised controlled trials whereby n-3s 205 
were administered to participants by supplementation or diet with outcomes being all-cause 206 
mortality, cardiac death, sudden death, MI, and stroke. The authors found no significant 207 
relationship between n-3 supplementation and measured outcomes although a substantial 208 
limitation is evident when examining the dose of n-3 intake used in studies. Indeed, studies 209 
using a higher dose of n-3 supplement tended to show benefit yet they themselves were 210 
limited by small sample size and therefore did not carry weight in the analysis. A more recent 211 
meta-analysis(38) has also examined the relationship between n-3s and coronary risk as part of 212 
larger review of the relationship between all FAs and coronary risk. The authors showed that 213 
n-3 supplementation was found not to be significantly associated with a reduced risk of 214 
coronary event in randomised controlled trials, whereas dietary n-3 intake was inversely 215 
associated with coronary outcomes in prospective studies. Indeed this latter point is 216 
reinforced by the observation that a higher marine or dietary n-3 (EPA and DHA) intake is 217 
inversely associated with the development of HF(39). It may be argued that if there is 218 
discrepancy in the dietary evidence base for the general population, is it safe and justifiable to 219 
offer the same advice to HF patients.  220 
Considering all studies above regarding FAs and it is clear that the role of fat in HF is 221 
not as simple as once thought. Rather than focusing solely on the calorie content of lipid, we 222 
should consider the biological and metabolic effects various FAs may have, and use these to a 223 
potential therapeutic advantage. N-3 supplementation may be of some benefit in HF patients 224 
although it remains to be determined if such benefits could be gained from increasing intake 225 
from dietary sources. At present there are no recommendations for HF patients in terms of 226 
omega-9 (n-9) FAs and so it would be of use if appropriate studies were performed to 227 
examine the effects of increasing n-9 FA consumption in addition to n-3s in this patient 228 
group.  229 
 230 
Sodium and fluid restrictions in heart failure 231 
HF is characterised by altered renal perfusion which itself leads to increased 232 
sympathetic activation and stimulation of the renin-angiotensin-aldosterone system (RAAS). 233 
Sodium and fluid are retained leading to increased circulating volume in an attempt to 234 
preserve cardiac output. However combined with fluid expansion, vasoconstriction caused by 235 
increased sympathetic activity raises blood pressure. Whilst initially beneficial, chronic 236 
activation of the RAAS and augmented sodium and fluid retention increases both afterload 237 
and preload, contributing to oedema formation and congestive symptoms(40). Reflecting the 238 
potential link between sodium intake and fluid accumulation, the ACCF/AHA advise sodium 239 
restriction in patients with symptomatic HF although this class of recommendation is IIa and 240 
carries a C level of evidence(10). Fluid restriction to 1.5 to 2.5 L/day is also suggested by the 241 
ACCF/AHA in those patients with NYHA class IV(10), in particular patients with 242 
hyponatraemia, with a similar recommendation by European guidance (although the latter 243 
carries no class or recommendation or level of evidence)(1). This is concerning given that 244 
sodium and fluid restriction are viewed as a mainstay of dietary intervention in HF and is 245 
further complicated by the presence of “salt-sensitive” phenotype, itself associated with 246 
increased mortality independent of blood pressure(41).  247 
Several studies have shown little clinical benefit in restricting sodium and/or fluid, 248 
although these may be confounded by their acute setting(42-44) (table 2). Compared to acute 249 
decompensated HF patients managed with a free-fluid regimen, acute decompensated HF 250 
patients managed with fluid restriction showed no improvement in time to clinical stability or 251 
time spent receiving intravenous HF therapy(42). An important limitation of this study is the 252 
difference in achieved fluid intake in both groups. In the free-fluid group, total daily fluid 253 
intake was 1466.6 mL versus 1074.3 mL in the fluid-restricted group. Although statistically 254 
significant, clinically a greater restriction may have led to potential improvements however as 255 
the authors note, this may have increased thirst and reduced compliance. Similarly, a 256 
restriction of sodium (800 mg/day) and fluid intake (800 mL/d) in acute decompensated HF 257 
patients increased thirst and led to no improvement in 30-day hospital readmission rates when 258 
compared to a control group receiving no such restriction(43). Furthermore, levels of brain-259 
type natriuretic peptide (BNP) were significantly higher in the restricted group at the end of 260 
the study. A very real confounding factor in these trials examining sodium restriction is their 261 
acute setting. Indeed, a low-sodium (1500 mg/d) diet proved to be more effective at reducing 262 
BNP in ambulatory HF patients with NYHA II/III when compared to a moderate sodium 263 
(2300 mg/d) diet(44). An important aspect of this study is the use of ambulatory HF patients as 264 
opposed to acute decompensated patients as described by references 39 and 40.  265 
To further complicate the issue of sodium restriction in HF patients a moderate in-266 
hospital sodium restriction (2800 mg/day) combined with hypertonic saline solution, 250 mg 267 
twice daily intravenous furosemide and 1000 mL fluid restriction in patients with HFrEF 268 
produced a greater improvement in diuresis and natriuresis when compared to a group of HF 269 
patients receiving a greater sodium restriction (1800 mg/day) and no hypertonic saline 270 
solution. These patients were discharged on their in-hospital sodium and fluid restrictions in 271 
addition to 50 – 125 mg twice daily furosemide. Those who maintained the moderate sodium 272 
intake showed reduction in the occurrence of the combined endpoint of mortality and hospital 273 
readmission in comparison to the restricted group(45). The authors of this study speculate that 274 
the greater sodium intake during the hospital admission and discharge may improve serum 275 
sodium levels, chronically reduce neuro-hormonal activation and improve delivery of 276 
diuretics to the loop of Henle, thus increasing their action of diuresis (table 2).  277 
It is also relevant to consider in the context of sodium restriction that salt taste 278 
diminishes with age(46), and that restricting sodium in hospitalised HF patients may lead to an 279 
increased desire to satisfy the salt taste on discharge, further compounding difficulties of 280 
adhering to a low-sodium diet. This concept would support the observations of Aliti et al.(43). 281 
As such consideration needs to be given to the different HF populations (ambulatory or 282 
hospitalised) in addition to the support required for patients to adhere to such a diet upon 283 
discharge. Without support, we are expecting a great deal from the elderly HF population 284 
which may be an additional reason why low-sodium diets are so difficult to follow. It would 285 
also be prudent to note that restricting sodium intake in HF patients has been shown to be 286 
associated with reduced intake of other important nutrients such as calcium, phosphate, 287 
thiamine and folate(47) and therefore it would be advisable that patients discharged from 288 
hospital with low-sodium advice receive regular follow-up to ensure compliance and also so 289 
that dietary adequacy can be reviewed (table 2). 290 
 A recent Cochrane meta-analysis(48) has suggested that sodium restriction leads to 291 
increased plasma renin, aldosterone, adrenaline and noradrenaline, irrespective of whether the 292 
individual is hypertensive or not, and as such may aggravate features of decompensated HF 293 
and explain the outcomes in previously mentioned studies. Furthermore elevated levels 294 
plasma renin activity have been linked with increased mortality in patients with stable 295 
symptomatic HF NYHA class III-IV, irrespective of pharmacotherapy(49). In the analysis by 296 
Graudal et al.(48) the authors report that restriction of sodium to a sub-normal level resulted in 297 
a 1% and 3.5% decrease in systolic blood pressure (SBP) in normotensive and hypertensive 298 
individuals, respectively. They also suggested that in normotensives a greater duration of 299 
sodium restriction produced a larger reduction in SBP (estimated mean difference of 0.4 300 
mmHg), however the reduction in SBP following sodium restriction in hypertensive 301 
individuals did not appear to be time-dependent. It may be inferred from these observations 302 
that sodium-restriction may have a greater impact upon afterload in those HF patients with 303 
co-existing HTN who are salt-sensitive. Although HTN is more common in those individuals 304 
with HFpEF, it is not exclusive to this group and therefore examining the specific benefits of 305 
low-sodium diets in both hypertensive and non-hypertensive HFrEF and HFpEF populations 306 
would be of use. 307 
Considering different responses to sodium restriction between acute decompensated 308 
and compensated HF patients, in addition to those who may be more salt-sensitive, a well-309 
designed clinical trial comparing short and long term effects of sodium restriction is required 310 
not solely on the outcome of mortality but on additional clinically relevant factors such as 311 
quality of life and hospital re-admission. A key recommendation should be that any sodium 312 
and fluid sodium restrictions need be individualised based on the severity of HF, dose of 313 
diuretic, degree of fluid accumulation and the clinical setting. 314 
 315 
Dietary patterns and disease progression in heart failure 316 
Discussion of the dietary management of each individual comorbidity experienced by 317 
HF patients is beyond the scope of this review. However, is the author’s opinion that through 318 
appropriate nutritional education there is no reason why dietary patterns such as the 319 
Mediterranean or Dietary Approaches to Stop Hypertension (DASH) cannot be modified to 320 
account for comorbidities such as diabetes, COPD or gout, and act as an adjunct to traditional 321 
pharmacotherapy for these conditions in HF patients.  322 
 323 
DASH and Mediterranean Diet 324 
Cohort studies have identified several dietary patterns as cardioprotective. Famous 325 
examples include the Mediterranean and DASH diets(50). A dietary pattern approach is 326 
important as they acknowledge the synergistic effects of different foods, rather than focussing 327 
on a single nutrient and recently studies have examined diet patterns in relation to specific 328 
outcomes in HF(51). Higher intakes of salty foods are associated with a shortened time to 329 
transplantation in patients with advanced HF and increasing the intake of foods rich in 330 
monounsaturated and polyunsaturated fatty acids (MUFA and PUFA, respectively) from 331 
“occasionally” to “several times a week” was associated with approximately 50% reduction 332 
in risk of death/deterioration(51). Other interesting results from this study include the 333 
association between different foods groups. Saturated fat (SFA) was significantly associated 334 
with increased consumption of salty food, and inversely associated with MUFA and PUFA. 335 
Similarly, both MUFA and PUFA also positively correlated with fruits/vegetables/legume 336 
intake, thus suggesting that the consumption of one nutrient may predict other dietary 337 
components. This observation may be important for the clinician or dietitian when taking a 338 
diet history, and may allow a more rapid determination of diet quality. However, whilst 339 
interesting this study is limited by the use of the food frequency questionnaire (FFQ) and 340 
does not provide information on the amount of such nutrients consumed by the participants.   341 
The DASH diet has a recognised beneficial effect in delaying the incidence of HF(52) 342 
and should be examined for use in HF patients. Such a diet is typically low in SFA, with 343 
increased consumption of low-fat dairy, complex carbohydrate, fish and vegetables(50). This 344 
dietary pattern is in contrast to that of the UK population which typically consume a diet 345 
higher in refined carbohydrate and SFA, and lower in vegetables(53). If individuals with HF 346 
are required to change their diet, support and guidance to the most appropriate way of 347 
achieving an optimal nutrient intake should be provided. 348 
Hummel et al.(54) demonstrated a significant improvement in ventricular diastolic 349 
function in 13 patients with HFpEF when these patients were provided with a sodium-350 
restricted DASH diet (DASH/SRD; 50 mmol/2100 kcal). Specifically, adherence to this 351 
dietary pattern improved EF by 8% and increased stroke volume by approximately 11%. 352 
Whilst impressive, the relatively small sample size and feeding protocol (controlled feeding 353 
with prepared meals) mean that such a finding may not be observed in free-living individuals 354 
with HF. Also, the nature of the population studied means that this finding may also be only 355 
linked to those with HTN and HFpEF (table 3). The Geriatric Out of Hospital Randomised 356 
Meal Trial in Heart Failure (GOURMET-HF) is one such study that will address if such 357 
findings can be reproduced using a home-delivered low-sodium meal, examining quality of 358 
life and cardiac functional parameters, although this study itself is still limited by the 359 
provision of meals(55). 360 
Levitan et al.(56) studied women enrolled in the Women’s Health Initiative who were 361 
admitted to hospital with HF to identify if adherence to a Mediterranean or DASH diet 362 
pattern influenced CVD mortality. Following a median of 4.6 years of follow-up there were 363 
1,385/3,215 deaths following HF hospitalisation. When stratified into quartiles, greater 364 
adherence to either the Mediterranean or DASH diet was associated with a substantial 365 
reduction in the hazard rate (HR) associated with mortality. Specifically, the HR for death 366 
was 16% and 15% lower in the DASH and Mediterranean diet group, respectively, although 367 
only reaching significance in the DASH group. Further analysis of the dietary intake of either 368 
Mediterranean or DASH patients revealed that greater adherence to each diet was associated 369 
with increased consumption of fruit and vegetables, nuts, legumes, whole grains and fish, and 370 
reduced intake of sweetened beverages and red and processed meat. However important 371 
limitations of this study were acknowledged by the authors, including difficulty in recording 372 
sodium, fluid and olive oil intake, in addition to the group being of those diagnosed with 373 
HFpEF. Whilst the results may be promising for the DASH diet, they do not support the 374 
advocacy for the Mediterranean-style diet, despite a favourable trend. However, previous 375 
cross-sectional data have shown that adherence to a Mediterranean Diet is associated with 376 
improved diastolic function in individuals with congestive HF (CHF)(57) (table 3) and 377 
subsequent studies have shown the Mediterranean Diet to reduce HF biomarkers in 378 
individuals at high risk CVD(58). Therefore at present, the role of the Mediterranean Diet in 379 
the management of HF remains to be fully examined. There is a clear need for large, 380 
randomised trials investigating if the improvement in mortality rate observed in the DASH 381 
group is driven by the restriction in sodium or a rather combined effect of diet and sodium 382 
restriction, and whether the Mediterranean diet has a role in the management of HF.   383 
 384 
Low carbohydrate and high protein  385 
There are several interesting reports regarding the use of low-carbohydrate diets in 386 
humans with HF. However, an important limitation of some of these studies cited is that they 387 
are almost exclusively conference abstracts and so caution should be exercised when 388 
interpreting them. Nonetheless, in patients with HF and right-ventricular dysfunction a diet 389 
classified as low in carbohydrate (40% carbohydrate, 40% fat, 20% protein) has been shown 390 
to be effective at increasing weight loss and improving oxygen saturated when compared to a 391 
conventional diet containing 50% of energy as carbohydrate(59). In addition the authors report 392 
an improvement in HF functional class. Like many HF trials, the study suffered from a 393 
relatively small sample size and short duration, including 21 individuals studied for a 394 
duration of 2 months. Therefore the long-term consequences of such a pattern remain 395 
unknown in HF patients. Importantly, this study highlights a key issue facing nutritional 396 
interventions: how diets are defined. Forty percent energy as carbohydrate may be regarded 397 
by many as not being ‘low carbohydrate’ and is consistent with that achieved in the 398 
PREDIMED study(60) (widely defined as a Mediterranean Diet). It would be appropriate for 399 
the The National Heart, Lung, and Blood Institute (NHLBI) and NIH Office of Dietary 400 
Supplements (ODS) working group(61) to also consider a standard protocol for reporting the 401 
nutritional composition of experimental diets in HF studies to facilitate greater comparison of 402 
dietary interventions, in addition to their other current recommendations (table 3). 403 
Modifying protein intake has been shown to be effective in reducing weight in obese 404 
patients (mean BMI 37.3 kg/m2) with NYHA class II-III HF. Evangelista et al.(62) compared a 405 
12-week hypocaloric diet (1200-1500 kcal/d) containing (as percentage of energy) 30% 406 
protein, 40% carbohydrate and 30% fat to a standard protein, hypocaloric diet (55% total 407 
energy from carbohydrates, 15% from protein, and 30% from fat) or the recommendations by 408 
the AHA. The authors noted that the high protein hypocaloric diet led to a greater reduction 409 
in % body fat and improved the patient’s quality of life (assessed by the Minnesota Living 410 
with Heart Failure Questionnaire). However, this study was performed in 5 individuals and is 411 
therefore severely limited by the small sample size (table 3). At present, there are no 412 
available large-scale dietary trails investigating protein intake and cardiac structure and 413 
function, functional status, and quality of life in HF patients although these are in 414 
development(63). 415 
 416 
The obesity paradox 417 
Studies 58 and 61 suggest a beneficial effect of weight loss in HF patients however it is 418 
important to recognise that uncontrolled weight loss in HF is linked with increased incidence 419 
of mortality(3). The importance of weight in HF patients has frequently been examined as part 420 
of the obesity paradox. The obesity paradox refers to observations that link the presence of 421 
obesity (and in some instances overweight) in HF patients with improved survival in 422 
comparison to lean counterparts. Horwich et al.(64) was one of the first groups to demonstrate 423 
the inverse relationship between weight and mortality in patients with HF. In this study, the 424 
majority of participants were of NYHA class IV, had an EF of 22% with obese patients more 425 
likely to have diabetes and HTN. Following multivariate analysis overweight and obesity 426 
were found to be associated with a significant survival benefit at 2 years with the worst 427 
prognosis seen in those who were underweight, followed by those who were classified as 428 
recommended weight. Importantly, whilst this study is used to draw evidence to the 429 
protective nature of obesity, the survival benefit was not evident at 5 years follow-up. In 430 
addition, categorisation of patients as underweight at baseline may not have accounted for 431 
unintentional weight loss prior to the study. Importantly this study was only performed in 432 
individuals with HFrEF and therefore may not apply to those with HFpEF. Despite this, 433 
subsequently larger meta-analysis studies have further reinforced this observation. 434 
Oreopoulus et al.(65) analysed a total of nine observational studies demonstrating that both 435 
overweight and obesity were associated with a reduced relative risk of all-cause and 436 
cardiovascular mortality when compared to patients with normal BMI levels. Regrettably the 437 
authors of this study did not extract data on EF however a more-recent a meta-analysis 438 
examined if HF subtype (HFrEF vs. HFpEF) impacted upon the obesity paradox. Using 439 
individual patient data Padwal et al.(66) demonstrated the existence of a U-shaped relationship 440 
between BMI and all-cause death in both HFrEF and HFpEF patients. In patients with HFrEF 441 
or HFpEF, the lowest hazard ratio for all-cause mortality was observed when comparing 442 
those individuals with a BMI between 30-34.9 kg/m2 against the reference BMI range of 443 
22.5-24.9 kg/m2. In both subtypes a BMI less than 22.5 kg/m2 was associated with a higher 444 
risk of all-cause death.  445 
There may be several mechanisms behind the proposed obesity paradox in HF. It is 446 
well-known that advanced HF is associated with cachexia(8) and in this regard, greater 447 
adiposity may simply reflect greater body energy stores and hence greater resistance to the 448 
metabolic changes associated with the cachexic state. As shown by Padwal et al.(66) 449 
individuals who were obese were also more likely to be receiving cardiovascular medication, 450 
potentially suggesting greater clinical input and therefore greater clinical management of 451 
their condition. It should however be noted that this was adjusted for in their study with no 452 
effect upon their findings. Also the use of BMI as a marker of fatness in HF has been 453 
questioned, with more accurate measurements of body composition being proposed(67). The 454 
presence of the obesity paradox means we may need to re-examine advice to achieve a 455 
healthy weight in HF patients and raises important questions regarding the role of weight loss 456 
(as described in Olvera et al.(59) and Evangelista et al.(62)) on the outcome of mortality. There 457 
may be a point where excess weight is not associated with any additional benefit but 458 
conversely increases risk. Indeed, in morbidly obese (BMI ≥40 kg/m2) HF patients the 459 
obesity paradox is absent(68). Therefore one may conclude that in those individuals with 460 
morbid obesity, intentional weight loss may be beneficial in terms of reducing mortality rate 461 
however this should be carefully monitored and controlled. In lower BMI categories a 462 
reduction in weight may improve clinical symptoms and disease classification, but may 463 
impact negatively on long-term survival. It would be useful for future studies examining the 464 
relationship between bodyweight and HF mortality to assess adipose tissues deposits (both 465 
visceral and subcutaneous) and lean mass, in additional to cardiorespiratory fitness following 466 
weight loss. 467 
 468 
Nutritional Messages – the role of the dietitian 469 
A key aspect of implementing a dietary strategy is addressing pre-conceived ideas and 470 
beliefs regarding nutrition. A tailored nutritional message to patients with HF is sufficient to 471 
alter patients’ views and attitudes towards medications, adherence to a sodium-restricted diet 472 
and self-monitoring(69). Further support for the importance of nutritional input can be derived 473 
from Arcand et al.(70). In this 3 month study, HF patients randomised to a dietitian-led 474 
education group showed greater improvements in salt reduction in comparison to usual care 475 
(self-help literature). Whilst such a frequent dietetic input may be unlikely in the current 476 
health-care setting, clinicians reviewing their patients may wish to follow-up nutritional 477 
advice and reinforce nutritional messages at every opportunity. Indeed, frequent nutritional 478 
counselling with HF patients may improve knowledge surrounding foods and reduce 479 
admissions. In HF patients a low level of sodium knowledge has been shown to be associated 480 
with a significantly greater odds ratio for hospital readmission for HF(71). Using the Test of 481 
Functional Health Literacy in Adults (TOFHLA) tool, sodium knowledge was associated 482 
with a low health literacy score. When nutritional interventions are combined with 483 
appropriate educational session substantial improvement in quality of life and disease score 484 
can be seen. For example, a nutritional intervention consisting of 2000-2400 mg/d sodium, 485 
50-55% (as % energy) carbohydrate, 15% protein, <10% SFA, 15% MUFA and 10% PUFA 486 
coupled with written and oral instruction from a dietitian led to a significant improvement in 487 
HF classification and quality of life when compared to a control group receiving general 488 
nutritional advice(72). Indeed the improvement in HF classification was reflected by a 489 
significant reduction in the number of individuals with NYHA class II and III and an increase 490 
in the number of those with class I by the end of the study (table 4). 491 
 492 
As such, this would suggest that by using appropriate methods of patient education 493 
and trained individuals it is never too late to make important and significant dietary changes 494 
that may improve quality of life.  495 
 496 
Discussion and conclusions 497 
HF remains a chronic and debilitating condition. Whilst the value of dietary 498 
manipulation is well-known in the primary, secondary and tertiary prevention of CVD it is 499 
undervalued in patients with HF and is reflected by the paucity of data in guidelines. Despite 500 
a large body of experimental data produced from animal models of HF examining the effect 501 
of different diet compositions, this has not translated into human trials. From animal trials it 502 
is clear that the traditional demonisation of fat may not be justified in HF, and human studies 503 
should be designed to evaluate the therapeutic effectiveness of cardioprotective fats in HF. 504 
Within this, consideration should be given to the underlying HF aetiology in addition to other 505 
comorbidities. Indeed by manipulating dietary nutrient composition it is possible for those 506 
individuals with other comorbidities to benefit from the potential therapeutic nature of food.  507 
Studies that have been published in this field – albeit largely observational – now 508 
suggest that diet advice in this area may need to be re-examined, with the traditional 509 
cardioprotective diets such as the Mediterranean and DASH potentially being of benefit. 510 
Such diet patterns have been shown to increase the consumption of cardioprotective food 511 
items such as fruit and vegetables, nuts, legumes, whole grains and fish and are likely to have 512 
additional health effects beyond HF.  513 
It is simple to decide what foods an individual should consume, yet much more 514 
difficult to actually achieve this. Regular nutritional education has been shown to lead to 515 
better adoption of a prescribed diet and may lead to improved overall nutritional status. In 516 
some studies, this has also translated to improvements in quality of life and reduced severity 517 
of symptoms when delivered by nutritionally-trained individuals. The feasibility of such a 518 
means of improving nutritional knowledge is clearly in need of evaluation, given the potential 519 
cost such a service may incur.   520 
Although the studies presented in this review are promising, many are limited by 521 
small sample sizes, short duration and observational study design. It is therefore a 522 
requirement that in order to progress towards better evidence-based dietary advice for 523 
patients with HF, larger, longer, randomised clinical trials are needed. Such studies should 524 
account for differences in HF subtype (HFrEF versus HFpEF) and have clearly defined 525 
clinical endpoints. In addition, there is a requirement for standardisation of dietary reporting. 526 
The studies highlighted in this review provide a potential starting point for the development 527 
of future trials, and fundamentally demonstrate that in addition to fluid and sodium, 528 
consideration should be given to other dietary components. 529 
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Table 1 abbreviations 
SFA, saturated fat; TAG, triacylglycerol; PET, positron emission tomography; EF, ejection 
fraction; NYHA, New York Heart Association; BMI, body mass index; FBS, foetal bovine 
serum; BSA, bovine serum albumin; FA, fatty acid; MS, mass spectrometry; DNA, 
deoxyribonucleic acid  SCD, stearoyl-CoA desaturase; TAC, transverse aortic constriction; 
NMR, nuclear magnetic resonance; HF, heart failure; DAG, diacylglycerol; PPAR-, 
peroxisome proliferator activated receptor alpha; mRNA messenger RNA;  PUFA, 
polyunsaturated fatty acid; EPA, eicosapentaenoic acid; DHA docosahexaenoic acid; MI, 
myocardial infarction. 
 
Table 2 abbreviation 
BNP, brain natriuretic peptide; EF, ejection fraction; HF, heart failure; NYHA, New York 
Heart Association; BMI, body mass index; KCCQ, Kansas City Cardiomyopathy 
Questionnaire. 
 
Table 3 abbreviations 
EF, ejection fraction; NYHA, New York Heart Association; BMI, body mass index; VO2, 
maximal oxygen consumption; HFpEF, heart failure with preserved ejection fraction; DASH; 
dietary approaches to stop hypertension; CVD, cardiovascular disease; HFrEF, heart failure 
with reduced ejection fraction; AHA, American heart association; LHFQ, Minnesota Living 
With Heart Failure Questionnaire. 
 
Table 4 abbreviations 
EF, ejection fraction; NYHA, New York Heart Association; BMI, body mass index; KCCQ, 
Kansas City Cardiomyopathy Questionnaire; LHFQ, Minnesota Living With Heart Failure 
Questionnaire; TOFHLA, Test of Functional Health Literacy in Adults; SFA, saturated fat. 
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Table 1 Summary of studies presented in this review investigating the role of fatty acids in HF patients and experimental models  
Study Participant characteristics Study Design Measures and time points Key observations 
 
Berthiaume et al. 
(25) 
 
Male Wistar rats  
 
Control + standard diet: n = 9-10 
Control + high SFA: n = 9-10 
Intervention + standard diet: n = 9-10 
Intervention + high SFA: n = 9-10 
 
Control: sham procedure followed 
by 8 weeks normal diet (10% kcal 
fat) or a high SFA diet with 60% 
kcal from fat (25% palmitic acid, 
33% stearic acid, and 33% oleic 
acid) 
 
Intervention: Coronary artery 
ligation followed by 8 weeks normal 
diet or high SFA diet as above 
 
Cardiac function using echocardiography and pressure-volume 
catheter, plasma and metabolic parameters, and genomic 
expression  
 
Diet intervention for 8-weeks 
 
High SFA diet did not exacerbate 
ventricular remodelling associated with 
coronary artery ligation 
 
High SFA diet prevented decline in 
stroke volume associated with coronary 
artery ligation and improved function 
during stress tests 
 
Greater transcription of nuclear material 
in failing hearts from the high SFA diet 
compared to respective surgical controls 
 
Berthiaume et al. 
(26) 
 
Male Wistar rats  
 
Control + standard diet: n = 13-16 
Control + high SFA: n = 13-16 
Intervention + standard diet: n = 13-
16 
Intervention + high SFA: n = 13-16 
 
Control: sham procedure followed 
by 8 weeks normal diet (10% kcal 
fat) or a high SFA diet with 60% 
kcal from fat (25% palmitic acid, 
33% stearic acid, and 33% oleic 
acid) 
 
Intervention: Coronary artery 
ligation followed by 8 weeks normal 
diet or high SFA diet as above 
 
Cardiac function using echocardiography, pressure-volume 
catheter and working-heart perfusions, plasma and tissue 
metabolite analysis, and genomic expression 
 
Diet intervention for 8-weeks 
 
Cardiac TAG significantly increased 
following high-SFA diet  
 
High SFA diet prevented decline in EF 
and stroke work observed in dietary 
control 
 
Failing hearts from rats fed the high 
SFA diet showed normalisation of 
glucose and oleate oxidation compared 
to dietary controls  
 
Tuunanen et al. 
(27) 
 
Total participants: n = 24 
Control group: n = 8 
Intervention group: n = 18 
 
Control group: 75.0% men 
Intervention group: 77.7% men 
 
Control group EF: 66.0%  
Intervention group EF: 33.0% 
 
Control group NYHA class: 0.0 
Intervention group NYHA class: 2.2 
 
Control group BMI: 26.0 kg/m2 
Intervention group BMI: 28.0 kg/m2 
 
Race and weight not reported 
 
 
Prospective study 
 
Both groups received Acipimox 
(250 mg orally twice daily) 
 
Myocardial perfusion and oxidative metabolism via PET, cardiac 
dimensions and function, and insulin sensitivity 
 
Baseline and after treatment 
 
Comparable levels of β-oxidation at 
baseline between groups 
 
Acipimox reduced cardiac work and 
cardiac efficiency in the intervention 
group only 
28 
 
Of note is that all patients had 
idiopathic dilated cardiomyopathy  
 
Listenberger et al. 
(31) 
 
CHO and 25RA cells, and Dgat1-/- 
fibroblasts 
 
Cells cultured in knockout 
Dulbecco's modified Eagle's 
medium supplemented with 10% 
FBS, 1 mM/L-glutamine, 50 
units/ml penicillin G sodium, and 50 
units/ml streptomycin sulphate. Cell 
culture incubated with palmitate 
and/or oleate bound to BSA at 6.6:1 
molar ratio 
 
Cells supplemented with FA media 
for 6 hours with 14C-labelled 
palmitate 
 
Apoptosis, uptake and accumulation of palmitate, lipid 
accumulation palmitate incorporation into triacylglycerol, MS for 
ceramide and TAG, enzyme activity  
 
DNA laddering measured after 26* hours 
 
Palmitate, neutral lipid accumulation, alterations in lipid 
composition and lipotoxicity measured after 6 hours of incubation 
with different FAs 
 
*SCD activity measured at 0, 18, 24 and 28 hours 
 
Palmitate-associated apoptosis and 
DNA laddering was prevented with co-
incubation with oleate 
 
Oleate prevented increase in ceramide 
associated with palmitate 
 
Increased activity of SCD associated 
TAG synthesis and resistance to 
palmitate-induced apoptosis  
 
Oleate promoted neutral lipid 
accumulation and led to greater 
incorporation of palmitate into TAG 
 
Failure of Dgat1-/- fibroblasts to 
accumulate TAG was associated with 
cell death 
 
O’Donnell et al. 
(33) 
 
3-week old male Sprague Dawley rats 
 
Control group: n = 16  
Intervention group: n = 18  
 
Control: sham procedure 
 
Intervention: pressure overload 
model of cardiac failure via TAC  
 
 
 
Substrate metabolism using NMR, cardiac function, lipid content 
and turnover 
 
Hearts excised 10-12 weeks post-banding and perfused 
 
 
 
Oxidation of TAG was not evident in 
failing hearts yet was observable in 
control rats 
 
TAG turnover significantly reduced in 
HF compared to control hearts 
 
TAG turnover uncoupled from 
workload in failing hearts 
 
Reduced ability to oxidise endogenous 
TAG was not matched by increase in 
exogenous oxidation of palmitate 
 
Lahey et al. (34) 
 
3-week old male Sprague Dawley rats  
 
Control oleate: n = 10-15 
Control palmitate: n = 10-15 
Intervention oleate: n = 10-15 
Intervention palmitate: n = 10-15  
 
Control: sham procedure 
 
Intervention: pressure overload 
model of cardiac failure via TAC  
 
 
Ex vivo cardiac function and metabolism measured following 13C-
labelled palmitate and oleate perfusion, TAG dynamics, DAG and 
ceramide content, and protein expression 
 
Hearts excised 12 weeks post-banding and perfused 
 
 
TAC + oleate prevented decline in 
contractility seen in TAC + palmitate 
 
TAC + oleate preserved normal TAG 
turnover and had greater TAG 
enrichment 
 
TAC + palmitate hearts had lower levels 
of DAG and increased C16 ceramide   
 
TAC + oleate leads to preservation of 
PPAR-α target gene mRNA 
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Tavazzi et al. (35)  
 
Randomised 7046 patients Excluded 
71 
Total participants: n = 6975 
Control group: n = 3481 
Intervention group: n = 3494 
 
Control group: 78.8% men 
Intervention group: 77.8% men 
 
Control group EF: 33.2%  
Intervention group EF: 33.0% 
 
Control group NYHA class: 63.2% II, 
34.1% III, 2.7% IV 
Intervention group NYHA class: 
63.7% II, 33.7% III, 2.9% IV 
 
Control group BMI: 27.0 kg/m2 
Intervention group BMI: 27.0 kg/m2 
 
Race and weight not reported 
 
Randomised control trail 
 
Control group: placebo 
 
Intervention group: 1 g/d n-3 PUFA 
(850-882 mg EPA and DHA ratio 
1:1.2) 
 
All participants were also randomly 
assigned to 10 mg/d oral 
rosuvastatin 
 
Study power of 90% 
 
Cardiovascular examination, vital signs, 12-lead 
electrocardiogram, compliance with study protocol, assessment of 
adverse events and blood biochemistry 
 
Primary outcome(s); time to death, and time to death or admission 
to hospital for cardiovascular reasons 
 
Secondary outcome(s): cardiovascular mortality or admission for 
any reason, sudden cardiac death, admission for cardiovascular 
reasons, admission for HF, MI and stroke 
 
Baseline, 1, 3, 6, and 12 months and then every 6 months until the 
end of the trial 
 
Median follow-up of 3.9 years 
 
Significantly greater all-cause mortality 
observed in control group 
 
Fewer deaths or hospital admissions 
attributable to cardiovascular reasons in 
intervention group 
 
Significant reduction in plasma TAG in 
intervention group 
 
 
 
SFA, saturated fat; TAG, triacylglycerol; PET, positron emission tomography; EF, ejection fraction; NYHA, New York Heart Association; BMI, body mass 
index; FBS, foetal bovine serum; BSA, bovine serum albumin; FA, fatty acid; MS, mass spectrometry; DNA, deoxyribonucleic acid  SCD, stearoyl-CoA 
desaturase; TAC, transverse aortic constriction; NMR, nuclear magnetic resonance; HF, heart failure; DAG, diacylglycerol; PPAR-, peroxisome proliferator 
activated receptor alpha; mRNA messenger RNA;  PUFA, polyunsaturated fatty acid; EPA, eicosapentaenoic acid; DHA docosahexaenoic acid; MI, 
myocardial infarction. 
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Table 2 Summary dietary sodium studies in HF patients presented in the current review 
Study Participant characteristics Study Design Measures and time points Key observations 
 
Travers et 
al.(42) 
 
Total participants: n = 67 
Control group: n = 33 
Intervention group: n = 34 
 
Control group: 48.4 % men 
Intervention group: 58.8 % men 
 
Control group EF: 40.2% 
Intervention group EF: 37.4% 
 
All patients had diagnosis of NYHA class 
IV HF 
 
Control group weight: 72.1 kg 
Intervention group weight: 76.2 kg 
 
Number screened, race and BMI not 
reported 
 
Randomised control trial 
 
Control group: free fluid 
 
Intervention: fluid restriction to 1 
L/d free fluid 
 
Renal profile measured for the duration of experiment. BNP 
assayed for first 7 days and alternative days following this until 
stability. Daily weight, HF status and medication review 
 
Primary end point: time in days to clinical stability 
 
Secondary endpoints: changes in renal parameters, BNP, duration 
of intravenous HF therapy and compliance with fluid restriction 
 
Followed until clinical stability 
 
 
Significant reduction in fluid intake in 
intervention group 
 
No significant difference in average 
weight loss, time to clinical stability, 
duration of intravenous HF therapy, 
BNP or renal profile at time of clinical 
stability between groups 
 
Aliti et 
al.(43) 
 
813 individuals screened 
738 excluded 
Total participants: n = 75 
Control group: n = 37 
Intervention group: n = 38 
 
Control group: 64.8 % men 
Intervention group: 73.6 % men 
 
Control group EF: 24.6% 
Intervention group EF: 27.4% 
 
Control group NYHA class: 45.9% III, 
48.6% IV 
Intervention group NYHA class: 47.3% 
III, 42.1% IV 
 
Control group weight: 82.4.0 kg 
Intervention group weight: 78.0 kg 
 
Race and BMI not reported 
 
Randomised control trial 
 
Control group: 3-5 g/d sodium 
intake, minimum fluid intake of 2.5 
L/d 
 
Intervention group: 800 mg/d 
sodium and 800 mL/d fluid 
 
Daily assessment of perceived thirst, weight, use of intravenous 
diuretics, vasodilators and inotropes and clinical congestion score 
 
Serum biochemical analysis 
 
Primary outcome: weight loss and clinical stability during hospital 
stay (measured at 3 days) 
 
Secondary outcomes: assessment of thirst and hospital 
readmission within 30 days of discharge 
 
30-day follow-up 
 
No statistical difference in length of 
stay, weight loss clinical congestion 
score, intravenous medications, 
laboratory tests or 30-day readmission 
score. 
 
Rating of thirst was significantly 
increased in intervention group 
compared with control. 
 
Intervention group showed significantly 
greater congestion at 30-day follow-up 
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Colín-
Ramirez et 
al.(44) 
 
451 individuals screened 
413 excluded 
Total participants: n = 38 
Control group: n = 19 
Intervention group: n = 19 
 
Control group: 38.9% men 
Intervention group: 36.8 % men 
 
Control group EF: 46.5% 
Intervention group EF: 34.5% 
 
Control group NYHA class: 84.2 % II, 
15.8 % IV 
Intervention group NYHA class: 94.7% II, 
5.3% IV 
 
Control group BMI categories:  
0.0% <18.5 kg/m2, 21.1% 18.5-24.9 kg/m2, 
26.3% 25.0-29.9 kg/m2, 52.6% ≥ 30 kg/m2 
Intervention group BMI categories: 0.0% 
<18.5 kg/m2, 10.5% 18.5-24.9 kg/m2, 
26.3% 25.0-29.9 kg/m2, 63.2% ≥ 30 kg/m2 
 
Population 95% white, 3% Afro-American 
and 3% South Asian 
 
Weight not reported 
 
 
Randomised control trial 
 
Control group: moderate sodium 
intake (<2300 mg/d) 
 
Intervention group: low sodium 
intake (<1500 mg/d) 
 
Both groups were prescribed 50-
55% dietary kcal from carbohydrate, 
15-20% protein and 25-30% lipids, 
and were provided with a sample of 
6 daily menus according to their 
energy requirements 
 
3-day food record during week prior to clinical visit (2 weekdays 
+ 1 weekend day) 
 
Serum biochemical analysis, BNP 
 
Quality of life using KCCQ  
 
Baseline, 3 months and 6 months follow-up 
 
 
 
2 patients dropped-out and 1 died 
 
Both groups significantly reduced 
sodium intake compared to baseline 
values 
 
At 6 months median BNP significantly 
reduced in the intervention group but 
did not differ between groups 
 
Median quality of life scores improved 
significantly in the intervention group 
and trended to improve in the control 
group. 
 
No change in NYHA classification 
between groups was observed 
 
Paterna et 
al.(45) 
 
2 phases 
 
Phase 1 
4728 screened. 1927 participants met entry 
criteria 
Total participants: n = 1927 
Control group: n = 974 
Intervention group: n = 953 
 
Control group: 37.1% men 
Intervention group: 36.9 % men 
 
Control group EF: 34.4% 
Intervention group EF: 33.7% 
 
Control group weight: 84.5 kg 
Intervention group weight: 82.7 kg 
 
 
Randomised control trial 
 
Phase 1 
Control group: Intravenous infusion 
of furosemide (250mg) twice daily, 
low-sodium diet (1.8 g/day), and 
1000 mL/d fluid restriction 
 
Intervention group: Hypertonic 
saline solution (150 mL of 1.4%-
4.6%) twice daily, intravenous 
infusion of furosemide (250 mg) 
twice daily, moderate-sodium diet 
(2.8 g/day), 1000 mL/d fluid 
restriction 
 
Phase 2  
 
 
Serum biochemical analysis, BNP, 24 hour natriuresis and 
diuresis, clinical and pharmacological assessment and cardiac 
function 
 
Primary outcomes: death or first hospitalisation for worsening HF 
 
Secondary outcomes: death from cardiac cause, hospitalisation for 
cardiac causes and combined end point of death from cardiac 
cause or hospitalisation for a change for a cardiac cause and 
change in NYHA classification 
 
Phase 1 
Baseline and discharge 
 
Phase 2 
Every week for first month, every month for first 6 months and 3 
monthly thereafter 
 
Phase 1 
 
Significant increase in diuresis observed 
in both group from admission to 
discharge although was significantly 
greater in the intervention group 
 
Natriuresis was significantly greater in 
the intervention group 
 
Significant increase in serum sodium 
concentration in intervention group. No 
increase in control group 
 
Significantly lower BNP in intervention 
group at discharge when compared to 
control group 
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All participants were NYHA class III at 
entry 
 
Phase 2 
Total participants: n = 1927 
Control group: n = 974 
Intervention group: n = 953 
 
Control group: 36.4% men 
Intervention group: 37.3 % men 
Control group NYHA: 83.4 % I, 16.8 % II 
Intervention group NYHA: 77.2% I, 
22.8% II 
 
BMI and race not reported 
 
 
 
 
Groups from phase 1 were 
continued on respective sodium-
restricted diets as out-patients 
Greater number of patients moving from 
NYHA class III to class I following 
intervention  
 
Phase 2 
 
156 subjects from phase 1 did not 
complete phase 2, leaving 1771 subjects 
who completed the study (control group 
n = 890; intervention group n = 881) 
 
BNP significantly lower in intervention 
group when compared to control group. 
 
Greater weight stability and diuresis in 
the intervention group 
 
Significant reduction in mortality and 
combined mortality + readmissions in 
the intervention group at 57 months 
follow-up 
 
Jefferson et 
al. (47) 
 
Total participants: n = 18 
77.7% men 
EF: 28.0% 
NYHA class: 22.2% I, 61.1 % II, 16.6% 
III 
BMI: 31.1 kg/m2 
 
Weight and race not reported 
 
 
 
Prospective study 
 
All participants received a <2,000 
mg/d sodium-restricted diet + 
individualised counselling from a 
dietitian before discharge and during 
study period (1 week) 
 
 
3-day food record collected prior to baseline and daily food record 
during study 
 
Baseline and 1 week follow-up 
 
2 subjects were excluded due to missing 
data. Final data based on N = 6    
 
Significant reduction in sodium and kcal 
intake at 1 week compared to baseline 
values 
 
Calcium, phosphate, thiamine and folate 
intakes were significantly reduced at 1 
week 
 
BNP, brain natriuretic peptide; EF, ejection fraction; HF, heart failure; NYHA, New York Heart Association; BMI, body mass index; KCCQ, Kansas City 
Cardiomyopathy Questionnaire.
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Table 3 Summary dietary studies in HF patients presented in the current review 
Study Participant characteristics Study Design Measures and time points Key observations 
 
Spaderna et 
al. (51) 
 
380 participants met inclusion criteria 
340 consented. 22 did not complete 
questionnaire 
Total participants: n = 318 
72.8% men 
EF: 21.5% 
NYHA class(N=316): 39.6% II, II-III, III, 
36.1% III-IV, 24.4% IV 
BMI: 25.9 kg/m2 
 
Race and weight, not reported 
 
Prospective study 
 
Participants recruited from The 
Waiting for a New Heart Study were 
mailed a food frequency 
questionnaire 
 
 
Food frequency questionnaire and fluid intake 
 
Resting heart rate, EF, mean blood pressure, peak VO2, serum 
sodium, interventricular conduction delay, ischaemic diagnosis 
(used to calculate Heart Failure Survival Score) 
 
Death on waiting list, high-urgency transplantation, elective 
transplantation, delisting due to clinical deterioration or 
improvement 
 
Baseline and occurrence of outcome listed above (mean follow-up 
of 462.8 days) 
 
 
 
6 participants were lost to follow-up 
 
Fluid intake > 2 L/d associated with 
hyponatraemia 
 
Greater intake of salty food significantly 
associated with shortened time to 
transplantation 
 
Consumption of foods high in 
MUFA+PUFA associated with reduced 
hazard ratio for death/deterioration 
 
Hummel et al. 
(54) 
 
Screened 22 participants 
Total participants: n = 14 
7.1% men 
EF: 66.0% 
NYHA class: 14.3% II, 85.7% III   
Weight: 94.0 kg 
BMI: 35.5 kg/m2 
Race not reported 
 
Total population classed as displaying 
HFpEF 
 
 
Prospective study 
 
Participants randomised to a DASH 
diet with a goal of 1150 mg 
sodium/2100 kcal  
 
3 day food diary, 24-hour urinary sodium and potassium, blood 
pressure and cardiac function 
 
Day 1 (blood pressure) and 2 (cardiac function), and 25 days 
follow-up (21 days of diet) 
 
1 participant withdrawn due to 
hyperkalaemia 
 
Significant decrease in systolic blood 
pressure following diet 
 
Arterial elastance, stroke volume and 
EF all improved significantly following 
dietary intervention 
 
Levitan et al. 
(56) 
 
Identified 4043 participants 
Excluded 828 
Total participants: n = 3215 
0.0 % men 
BMI: 30.5 kg/m2 
85.4% White not of Hispanic origin, 
10.5% Black, 1.7% Hispanic, 1.0% 
Asian/Pacific Islander, 0.5% American 
Indian/Alaskan Native 
 
No measures of cardiac function or NYHA 
classification or weight 
 
 
 
Prospective study 
 
Participants were taken from the 
Women’s Health Initiative dietary 
modification  and observational 
study and were followed from HF 
hospitalisation to date of death or 
last contact with participant prior to 
August 2009 
 
Modified block food frequency questionnaire, Mediterranean and 
DASH diet scores 
 
Median follow-up of 4.6 years 
 
1385 deaths occurred, of which 694 
attributable to CVD. 
 
Women who died were older, more 
likely to smoke, were less active and 
had a lower BMI 
 
Highest quartile* of Mediterranean and 
DASH scores had greater intake of fruit 
and vegetables, nuts, legumes, whole-
grains, low-fat dairy, fish and lower 
intakes of red and processed meat, in 
addition to sugar-sweetened beverages 
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Higher DASH score associated with 
significantly lower hazard rate of death. 
Non-significant trend for lower hazard 
rate for death following Mediterranean 
diet  
 
Vegetables, nuts, nuts and legumes and 
wholegrain inversely associated with 
mortality post hospitalisation from HF 
 
*tertitles for sugar-sweetened beverages 
due to limited range of intake 
 
 
Chrysohoou 
et al. (57) 
 
Total participants: n = 372 
84.4 % men 
BMI: 28.0 kg/m2 
All participants were of HFrEF (EF 
<40%).  
 
Race, NYHA class and EF were not 
reported  
 
Cross-sectional 
 
Statistical power of 87% 
 
Semi-quantitative food frequency questionnaire and 
Mediterranean diet score, cardiac function 
 
 
Greater adherence to Mediterranean diet 
associated with a significant 
improvement diastolic function and 
flow propagation 
 
Greater intake of fish, olive oil and 
vegetables associated with 
improvements in diastolic indices 
 
Olvera et al. 
(59) 
 
Total participants: n = 39 
Control group: n = 18 
Intervention group: n = 21 
 
Number randomised, sex, race, BMI, EF, 
and NYHA class not reported 
 
Note study performed in patients with HF 
and right ventricular dysfunction 
 
 
 
Randomised control trial 
 
Control group: standard diet with 
50% energy from carbohydrate, 
30% from fat and 20% from protein 
 
Intervention group: 40% energy 
from carbohydrate, 40% from fat 
and 20% from protein 
 
Sodium and fluid intake not 
available 
 
Bioelectrical impedance and anthropometry, stress test and 
laboratory assessments 
Baseline and 2 months follow-up 
 
Significant reduction in weight in 
intervention group 
 
Significantly greater number of 
individuals with improved symptoms in 
intervention group compared to control 
group 
 
Improvement in oxygen saturated 
following intervention 
 
Evangelista et 
al. (62) 
 
Total participants: n = 14 
Control group: n = 4 
Intervention group 1: n = 5 
Intervention group 2: n = 5 
 
Control group: 75.0% men 
Intervention group 1: 80.0% men 
Intervention group 2: 80.0% men 
 
Control group EF: 26.6%  
Intervention group 1 EF: 27.8% 
Intervention group 2 EF: 23.8% 
 
 
Randomised control trial 
 
Control group: AHA 
recommendations for healthy adults. 
No energy restrictions 
 
Intervention group 1: high protein 
hypoenergetic diet (40% total 
energy from carbohydrates, 30% 
from fat and 30% from protein)  
 
 
 
 
Anthropometry, functional status, biochemical measurements, 
LHFQ and 3-day food diary 
 
Baseline and 12 weeks follow-up 
 
Significantly greater weight loss in 
intervention group 1 compared to 
intervention group 2 and control group 
 
Trend toward increased lean mass in 
intervention group 1 
 
Greater improvement in LHFQ in 
intervention group 1 than in intervention 
group 2  
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Control group NYHA class: 25.0% II, 
75.0% III 
Intervention group 1 NYHA class: 40.0% 
II, 60.0% III 
Intervention group 2 NYHA class: 40.0% 
II, 60.0% III 
 
Control group weight: 109.8 kg 
Intervention group 1 weight: 110.8 kg 
Intervention group 2 weight: 99.5 kg 
 
Control group BMI: 40.7 kg/m2 
Intervention group 1 BMI: 37.3 kg/m2 
Intervention group 2 BMI: 35.9 kg/m2 
kg/m2 
 
Control group LHFQ: 70.9 
Intervention group 1 LHFQ: 68.5 
Intervention group 2 LHFQ: 73.0 
 
Control group peak VO2: 10. 
9 mL/kg/min 
Intervention group 1 peak VO2: 13.5 
mL/kg/min 
Intervention group 2 peak VO2: 12.7 
mL/kg/min 
 
Race not reported 
Intervention group 2: standard 
protein, hypoenergetic (55% total 
energy from carbohydrates, 30% 
from fat and 15% from protein) 
 
Both intervention groups 
participated in intensive 12-week 
supervised weight-loss intervention 
 
Meals plans designed to incorporate 
500-800 kcal/d deficit 
 
 
Significant improvement in VO2 peak in 
intervention group 1 
 
EF, ejection fraction; NYHA, New York Heart Association; BMI, body mass index; VO2, maximal oxygen consumption; HFpEF, heart failure with preserved 
ejection fraction; DASH; dietary approaches to stop hypertension; CVD, cardiovascular disease; HFrEF, heart failure with reduced ejection fraction; AHA, 
American heart association; LHFQ, Minnesota Living With Heart Failure Questionnaire 
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Table 4 Summary of nutritional education studies in HF patients presented in the current review 
Study Participant characteristics Study Design Measures and time points Key observations 
 
Sethares et 
al. (69) 
 
Recruited 88 participants 
8 withdrew and 10 died before follow-up 
Total participants: n = 67 
Control group: n = 37 
Intervention group: n = 33 
 
Control group: 43.2% men 
Intervention group: 51.5% men 
 
Control group: 89.2% white 
Intervention group: 93.9% white 
 
Control group EF: 38.8% 
Intervention group EF: 41.5% 
 
Control group NYHA class: 3 
Intervention group NYHA class: 3 
 
BMI and weight not reported 
 
Randomised control trial 
 
Control group: received usual care 
 
Intervention: received tailored 
message during hospitalisation, 1 
week and 1 month post-discharge. 
 
Health belief scales, LHFQ, medication and hospital readmission 
rates 
 
LHFQ determined at 1 month post-discharge 
Change in benefit and barriers towards medications, diet and self-
monitoring at 1 week and 1 month 
 
Readmission rate at 3 months 
 
 
 
No significant change in hospital 
readmissions between groups 
 
No change in quality of life scores 
 
Intervention led to a significant 
improvement in understanding benefits 
and barriers towards diet and self-
monitoring.  
 
No change to perceived benefit of 
medication between groups 
 
Arcand et al. 
(70) 
 
Recruited 50 patients  
3 excluded  
Total participants: n= 47 
Control group: n = 23 
Intervention group: n = 24 
 
Control group: 73.9% men 
Intervention group: 75.0% men 
 
Control group EF: 23.0% 
Intervention group EF: 22.0% 
 
Control group mean furosemide: 82 mg/d 
Intervention group mean furosemide: 90 
mg/d 
 
Weight, BMI, race or NYHA class not 
reported 
 
Randomised control trial 
 
Control group: Prescribed 2 g/day 
sodium diet and provided with self-
help low-sodium literature 
 
Intervention: Prescribed 2 g/d 
sodium diet, low sodium literature 
plus two education sessions with a 
dietitian 
 
3 day food record (including 2 weekdays + 1 weekend) 
 
Primary outcome: change in sodium intake 
 
Secondary outcomes weight, medication fluid 
 
Baseline and 3 month follow-up 
 
Significant reduction in dietary sodium 
intake following the intervention 
 
No change in dietary macronutrients 
between groups 
 
Kollipara et 
al. (71) 
 
 
Recruited 105 patients  
7 excluded  
Total participants: n = 97  
 
Prospective 
 
Participants grouped based on 
dietary sodium score 
 
Sodium knowledge assessed by Parkland Dietary Sodium 
Knowledge Test, TOFHLA 
 
90-day hospital readmission 
 
90-day hospital readmission inversely 
associated with sodium knowledge 
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Very low dietary sodium knowledge: n = 
40 
Not very low dietary sodium knowledge: n 
= 57 
 
Very low dietary sodium knowledge: 
63.0% men 
Not very low dietary sodium knowledge: 
70.0% men 
 
Very low dietary sodium knowledge: 
78.0% African American 
Not very low dietary sodium knowledge: 
82.0% African American 
 
BMI, weight, EF and NYHA class 
≤3: Very low dietary sodium 
knowledge 
 
≥4: Not very low dietary sodium 
knowledge 
 
 
 
 
 
 
Significant association between 
TOFHLA and dietary sodium 
knowledge following intervention 
 
Colín-
Ramirez et 
al. (72) 
 
Randomised 65 patients  
8 excluded or lost to follow-up 
Total participants: n= 58 
Control group: n = 31 
Intervention group: n = 27 
 
Control group: 61.3% men 
Intervention group: 33.3% men 
 
Control group EF: 42.3% 
Intervention group EF: 40.0% 
 
Control group NYHA class: 56.7% I, 
30.0% II. 13.3% III 
Intervention group NYHA class: 59.3% I, 
22.2% II, 18.5% III 
 
Control group BMI: 27.3 kg/m2 
Intervention group BMI: 27.5 kg/m2 
 
Control group weight: 67.6 kg 
Intervention group weight: 63.9 kg 
 
Race not reported 
 
Randomised control trial 
 
Control group: traditional dietary 
advice regarding sodium and fluid 
intake 
 
Intervention: Prescribed 2-2.4 g/day 
sodium, 50-55% dietary kcal from 
carbohydrate, 15% protein and 30-
35% lipids. Fluids limited to 1.5 
L/d. Received written and oral 
advice from a dietitian 
 
Serum biochemical analysis, adapted KCCQ score and LHFQ, 
physical activity and 3-day food questionnaire (2 weekdays + 1 
weekend) 
 
Baseline and 6 month follow-up 
 
Significant reduction total fat and SFA 
following intervention 
 
Intervention led to significant reduction 
in sodium and fluid 
 
Significant reduction in number of 
NYHA class II and II and increase in 
class I in the intervention group. 
 
EF, ejection fraction; NYHA, New York Heart Association; BMI, body mass index; KCCQ, Kansas City Cardiomyopathy Questionnaire; LHFQ, Minnesota 
Living With Heart Failure Questionnaire; TOFHLA, Test of Functional Health Literacy in Adults; SFA, saturated fat. 
